OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Rugo on Pathway Blockade in Breast Cancer

October 10th 2018

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses pathway blockade in breast cancer.

Resistance to PD-1 Checkpoint Blockade

October 9th 2018

Michelle Krogsgaard, PhD, associate professor, Department of Pathology, NYU Langone's Perlmutter Cancer Center, discusses mechanisms of resistance to PD-1 checkpoint blockade.

Dr. Westin on PARP Resistance in Ovarian Cancer

October 9th 2018

Shannon N. Westin, MD, MPH, clinical investigator, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses resistance to PARP inhibitors in patients with ovarian cancer.

Dr. Singal on the Potential for Immunotherapy in HCC

October 9th 2018

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses the potential of immunotherapy in the treatment landscape of hepatocellular carcinoma.

Dr. Shah on the Current State of CAR T-Cell Therapy in Myeloma

October 9th 2018

Nina Shah, MD, associate professor, Department of Medicine, University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the current state of CAR T-cell therapy in multiple myeloma.

Dr. Esserman Discusses the I-SPY 2 Trial in Breast Cancer

October 9th 2018

Laura J. Esserman, MD, MBA, professor, University of California, San Francisco Helen Diller Comprehensive Cancer Center, 2018 Giant of Cancer Care® for Cancer Diagnostics, discusses the I-SPY 2 trial in breast cancer.

Dr. Hill on Recent Advances in Treatment of CLL

October 9th 2018

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses recent advances in the treatment of patients with chronic lymphocytic leukemia.

Dr. Steinberg on Treatment Approaches in Non-Muscle Invasive Bladder Cancer

October 9th 2018

Gary D. Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses treatment approaches in non-muscle invasive bladder cancer (NMIBC).

Dr. Kaplan on the RELEVANCE Trial in Follicular Lymphoma

October 9th 2018

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the RELEVANCE trial in previously untreated patients with follicular lymphoma.

Dr. Herzog on the Use of HIPEC in Ovarian Cancer

October 9th 2018

Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.

Dr. Link on the Current State of Treatment For Pediatric Cancer

October 8th 2018

Michael Link, MD, professor, Pediatrics, Stanford Cancer Institute, and a 2018 Giant of Cancer Care in Pediatric Oncology discusses the current paradigm for treatment in pediatric cancer.

Dr. Forster on Recent Data With Lurbinectedin in SCLC

October 8th 2018

Martin Forster, MD, a medical oncologist, University College London Hospitals, discusses data of lurbinectedin plus doxorubicin as a second-line therapy for patients with small cell lung cancer.

Dr. Shah Discusses Frontline Considerations for the Treatment of CML

October 5th 2018

Neil Shah, MD, PhD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco (UCSF) Program Leader, Hematopoietic Malignancies Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses frontline treatment considerations for patients with chronic myeloid leukemia.

Dr. Spigel Reflects on the PACIFIC Study in NSCLC

October 5th 2018

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, reflects on the results of the PACIFIC trial in patients with non–small cell lung cancer.

Dr. Becerra Discusses Dosing Strategies in CRC

October 5th 2018

Carlos Becerra, MD, medical oncologist, Texas Oncology, discusses dosing strategies in the treatment of patients with colorectal cancer.

Cosmo Smith on the Difference Between Clinical Liquidity and Financial Liquidity

October 5th 2018

P. Cosmo Smith, MBA, managing partner, Origin Commercial Ventures, discusses the difference between clinical liquidity and financial liquidity.

Dr. Whitman on the Partnership Between Atlantic Health System, TGen and Origin

October 5th 2018

Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses the partnership between Atlantic Health System, Translational Genomics Research Institute (TGen), and Origin Commercial Ventures.

Dr. Patterson on Off-Target Effects With TKIs in Pediatric CML

October 5th 2018

Briana Patterson, MD, assistant professor, Division of Endocrinology, Aflac Cancer Center, Department of Pediatrics, Emory University School of Medicine, discusses the off-target effects with tyrosine kinase inhibitors (TKIs) in pediatric patients with chronic myeloid leukemia (CML).

Dr. Powell on the Future of Immunotherapy in Ovarian Cancer

October 5th 2018

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses the future of immunotherapy in ovarian cancer.

Dr. Choueiri Discusses the CANTATA Trial in RCC

October 5th 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the CANTATA trial in renal cell carcinoma.